Sign up to save your podcasts
Or
Share Mary O'Brien, MD, FRCP - Moving Immune Checkpoint Inhibitors to Resected Early-Stage Non-Small Cell Lung Cancer: Emerging Strategies for Adjuvant Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Mary O'Brien, MD, FRCP - Moving Immune Checkpoint Inhibitors to Resected Early-Stage Non-Small Cell Lung Cancer: Emerging Strategies for Adjuvant Therapy
Please visit answersincme.com/MDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the impact of adjuvant immune checkpoint inhibitors (ICIs) on outcomes in patients with resected early-stage non-small cell lung cancer (NSCLC), and how to optimally integrate them into practice based on recent evidence. Upon completion of this activity, participants should be better able to: Review guideline-recommended adjuvant treatment options for patients with surgically resected early-stage NSCLC; Describe the clinical evidence for novel ICIs being investigated for the adjuvant treatment of surgically resected early-stage NSCLC; and Outline clinical considerations for the use of novel adjuvant ICIs in the management of patients with surgically resected early-stage NSCLC.
View all episodes
By Answers in CME
5
55 ratings
Please visit answersincme.com/MDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the impact of adjuvant immune checkpoint inhibitors (ICIs) on outcomes in patients with resected early-stage non-small cell lung cancer (NSCLC), and how to optimally integrate them into practice based on recent evidence. Upon completion of this activity, participants should be better able to: Review guideline-recommended adjuvant treatment options for patients with surgically resected early-stage NSCLC; Describe the clinical evidence for novel ICIs being investigated for the adjuvant treatment of surgically resected early-stage NSCLC; and Outline clinical considerations for the use of novel adjuvant ICIs in the management of patients with surgically resected early-stage NSCLC.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
JAMA Editors' Summary
129 Listeners
NEJM This Week
325 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
This Week in Cardiology
862 Listeners
JAMA Clinical Reviews
493 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
JAMA Medical News
90 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
CME in Minutes: Education in Primary Care
5 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners